LM 316
Alternative Names: LM-316Latest Information Update: 03 Dec 2025
At a glance
- Originator LaNova Medicines Limited
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-small cell lung cancer; Ovarian cancer; Triple negative breast cancer
Most Recent Events
- 03 Dec 2025 Preclinical trials in Non-small cell lung cancer in China (Parenteral) before December 2025 (LaNova Medicines pipeline, December 2025)
- 03 Dec 2025 Preclinical trials in Ovarian cancer in China (Parenteral) before December 2025 (LaNova Medicines pipeline, December 2025)
- 03 Dec 2025 Preclinical trials in Triple-negative-breast-cancer in China (Parenteral) before December 2025 (LaNova Medicines pipeline, December 2025)